甲钴胺联合依帕司他治疗糖尿病周围神经病变的临床效果及对患者氧化应激指标的影响

Clinical Efficacy of Mecobalamin Combined with Epalrestat in the Treatment of Diabetes Peripheral Neuropathy and Its Influence on Patients'Oxidative Stress Indicators

目的探究糖尿病周围神经病变患者采用甲钴胺联合依帕司他治疗的临床效果。方法选取2022年3月—2023年3月我院收治的50例糖尿病周围神经病变患者为研究对象,按随机数字表法将其分为对照组(n=25例)及观察组(n=25)。对照组采用甲钴胺治疗,观察组在此基础上采用依帕司他治疗。比较两组患者的临床疗效、氧化应激指标、神经症状、神经传导速度及不良反应的发生情况。结果观察组的治疗总有效率为84.00%,高于对照组的56.00%,差异有统计学意义(P<0.05)。治疗后,观察组的血清丙二醇水平高于对照组,超氧化物歧化酶水平、密歇根神经病变筛查量表评分均低于对照组,组间差异有统计学意义(P<0.05)。治疗后,观察组的正中神经、腓总神经运动神经传导速度、感受神经传导速度均快于对照组,组间差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论糖尿病周围神经病变患者采用甲钴胺联合依帕司他治疗的效果理想,可调节氧化应激反应,改善神经传导速度,且安全性较高。

Objective To investigate the clinical effect of mecobalamin combined with epalrestat in the treatment of diabetic peripheral neuropathy.Methods A total of 50 patients with diabetic peripheral neuropathy admitted to the hospital from March 2022 to March 2023 were selected as the research objects and were divided into a control group(n=25)and an observation group(n=25)according to random number table method.The control group was treated with mecobalamin,and the observation group was treated with epalrestat on this basis.The clinical efficacy,oxidative stress indicators,neurological symptoms,nerve conduction velocity and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 84.00%,higher than 56.00%of the control group,the difference was statistically significant(P<0.05).After treatment,the serum malondialdehyde level in the observation group was higher than that in the control group,and the superoxide dismutase level and Michigan Neuropathy Screening Instrument score were lower than those in the control group,the differences between the groups were statistically significant(P<0.05).After treatment,the motor nerve conduction velocities and sensory nerve conduction velocities of median nerve and common peroneal nerve of the observation group were faster than those of the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Mecobalamin combined with epalrestat is an effective treatment for diabetic peripheral neuropathy patients,which can regulate oxidative stress response,improve nerve conduction velocity,and has high safety.